Novartis announced US Food and Drug Administration approval of Cosentyx for polymyalgia rheumatica in a US release dated November 16, 2026, followed by a global announcement on November 17. For clinical researchers and research offices, the development connects the phase 3 REPLENISH trial with a new US indication and makes its endpoint definitions and regulatory documentation especially relevant.
The announcement and the November US label
The US announcement concerns Cosentyx, or secukinumab. The manufacturer’s current US prescribing information marks the PMR indication as a November 2026 change. Section 1.7 covers adults with an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. The release dates identify when Novartis announced the development; they do not establish the precise day of FDA action.
The announcement received separate newsroom coverage. Roushni Nair reported it for Investing.com on November 16, while RTTNews published a staff report on November 17. Both identified REPLENISH as the evidence behind the announcement.
What REPLENISH measured
The ClinicalTrials.gov record for NCT05767034 identifies Novartis Pharmaceuticals as sponsor and lists actual enrollment of 381. It describes an interventional phase 3 study with randomized allocation and parallel groups. Its masking fields identify participants, care providers, investigators and outcome assessors as masked. This randomized controlled trial compared secukinumab with placebo.
The registry’s primary outcome is sustained remission at week 52. Its definition combines remission at week 12 with the absence of recurrent PMR signs or symptoms, or a new diagnosis of giant cell arteritis, requiring escape or rescue treatment through week 52. These are study assessment windows. The outcome therefore describes a sustained, protocol-defined result rather than a single favorable assessment.
Complete sustained remission is a separate secondary outcome. The registry adds the absence of clinically relevant repeated elevations in erythrocyte sedimentation rate or C-reactive protein. Other registered secondary outcomes address cumulative glucocorticoid exposure, first use of escape or rescue treatment, fatigue and functional ability. Keeping these outcomes separate matters when comparing a headline result with the registered analysis plan.
The results carried into prescribing information
Section 14.8 of the November label describes three randomized groups. Table 16 presents the following selected Cosentyx-versus-placebo comparison for the PMR indication. The denominators below refer to that comparison, rather than the entire trial enrollment.
| Week 52 outcome | Cosentyx comparison group | Placebo |
|---|---|---|
| Sustained remission | 51 of 126; 40.5% | 26 of 127; 20.5% |
| Complete sustained remission | 31 of 126; 24.6% | 6 of 127; 4.7% |
The label defines complete sustained remission as sustained remission plus normalization of the two inflammatory markers. Its safety section also records higher proportions of urinary tract infections and hypersensitivity reactions in the Cosentyx comparison group, and a fatal case of cryptococcal meningitis in a treated participant. Those observations belong alongside efficacy findings in summaries of the evidence.
The European decision followed a separate process
The European Medicines Agency’s opinion summary records a positive CHMP opinion on September 17, 2026. It recommended a change to the marketing authorization and expressly distinguished that recommendation from a subsequent European Commission decision.
Novartis then announced Commission approval on October 21. The European wording concerns adults with an inadequate response to glucocorticoids or relapse during glucocorticoid taper. That earlier European development and the November US announcement are separate jurisdictional milestones, with separately worded indications. For multinational research records, a single undifferentiated approval date would erase that distinction.
Investigator, advocacy and sponsor reaction
In the US release, John Stone, identified as REPLENISH’s global principal investigator and a professor at Harvard Medical School and Massachusetts General Hospital, welcomed the development and emphasized the sustained-remission findings. Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation and CreakyJoints, emphasized an additional option for patients and clinicians.
Novartis US president Victor Bultó framed the announcement as an expansion of the medicine’s uses and the company’s research program. These are attributed perspectives in the sponsor’s release: an investigator’s assessment, an advocacy response and a company statement have different roles from the registered study outcomes and regulatory labeling.
Implications for research offices and evidence records
Our editorial assessment is that the immediate research-office task is document reconciliation. A useful evidence record would connect clinical trial registration, endpoint definitions, results and the applicable national label. It would retain each document’s date and jurisdiction, allowing readers to distinguish the trial’s completion from an approval announcement.
The registry gives March 14, 2023 as its first posting, September 10, 2025 as primary completion, February 16, 2026 as study completion and June 22, 2026 as its latest posted update. Those fields describe different events. Linking them to a clinical study report or a trial master file, where applicable, can preserve the evidence trail without substituting a press-release date for a study or regulatory milestone.
For university communications and research summaries, our interpretation is equally specific: retain the outcome name, comparison-group denominator and assessment window when describing the findings. A summary of sustained remission should not silently become a claim about complete sustained remission. These are editorial documentation recommendations, rather than new compliance obligations created by the announcement.
Further regulatory reviews remain in progress
The November 17 global announcement says additional regulatory reviews are ongoing, including in Japan. Any subsequent decision will be a further jurisdiction-specific development. Research teams tracking the program can distinguish that next regulatory milestone from the completed trial and the already announced US and European decisions.
Sources
- Novartis US: Cosentyx FDA approval announcement for PMR, November 16, 2026; checked November 17, 2026.
- Novartis: Cosentyx FDA approval announcement for PMR, November 17, 2026; checked November 17, 2026.
- Novartis: Cosentyx US prescribing information, November 2026 indication update, sections 1.7, 6.1 and 14.8; checked November 17, 2026.
- ClinicalTrials.gov: REPLENISH study record, NCT05767034, structured record, last update posted June 22, 2026; checked November 17, 2026.
- EMA: Cosentyx post-authorization summary of positive opinion, September 17, 2026; checked November 17, 2026.
- Novartis: European Commission approval for Cosentyx in PMR, October 21, 2026; checked November 17, 2026.
- Investing.com, Roushni Nair: Novartis wins FDA approval for Cosentyx in polymyalgia rheumatica, November 16, 2026; checked November 17, 2026.
- RTTNews Staff Writer: Novartis’ Cosentyx wins FDA approval as first anti-IL-17 biologic for polymyalgia rheumatica, November 17, 2026; checked November 17, 2026.







